Science 37 is a research-focused organization pioneering a new era of clinical trial execution through its patient-centric, technology-driven Decentralized Clinical Trial (DCT) operating model. Their mission is to accelerate biomedical research and development by making clinical trial participation more accessible to patients, regardless of their geographical location. By leveraging in-house mobile nursing, telemedicine, and proprietary technology platforms, Science 37 aims to improve patient recruitment, retention, and data quality, ultimately speeding up the delivery of new treatments to market. In early 2024, Science 37 was acquired by eMed, further enhancing its capabilities to deliver end-to-end DCT solutions.
The headquarters serves as the central hub for strategic leadership, global operations management, technology development, corporate governance, and administrative functions.
The office is situated in a modern business park environment, designed to facilitate collaboration and innovation, benefiting from the rich ecosystem of the Research Triangle Park.
The work culture at Science 37 emphasizes innovation, patient-centricity, collaboration, and agility. Employees are often driven by the mission to transform clinical research and improve patient access to trials. The environment encourages problem-solving and leveraging technology to overcome traditional research barriers.
Locating the headquarters in the Research Triangle Park area provides Science 37 with access to a highly skilled talent pool, proximity to leading research institutions and pharmaceutical companies, and a supportive business environment for life sciences and technology innovation.
Science 37 supports clinical trial operations globally, with the capability to conduct studies in numerous countries. Their decentralized model and technology platform enable them to reach patients across diverse geographies, including North America, Europe, Latin America, and Asia-Pacific. This global reach allows for broader patient access, diverse population enrollment, and efficient trial management regardless of physical office locations.
600 Park Offices Drive, Suite 300
Durham
North Carolina
USA
Address: N/A (Decentralized Model)
To support patient recruitment, trial conduct, and data collection globally, bringing trials directly to patients in their homes or local clinics. This includes operational support for North America, Europe, and Asia-Pacific regions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Science 37' leadership includes:
Science 37 has been backed by several prominent investors over the years, including:
The most significant executive event in the last 12 months was the acquisition of Science 37 by eMed, completed in January 2024. This led to a leadership transition with David Coman, formerly of eMed, becoming the CEO of Science 37.
Discover the tools Science 37 uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Science 37 typically uses a standard corporate email format. The most common structures observed are [first].[last]@science37.com or [first_initial][last]@science37.com.
[first].[last]@science37.com or [first_initial][last]@science37.com
Format
john.doe@science37.com
Example
80%
Success rate
PR Newswire • January 22, 2024
eMed announced the successful completion of its acquisition of Science 37 Holdings, Inc. This strategic move aims to combine eMed's telehealth and diagnostics capabilities with Science 37's expertise in decentralized clinical trials to create a comprehensive solution for modern clinical research....more
GlobeNewswire • October 26, 2023
Science 37 announced it had entered into a definitive agreement to be acquired by eMed, a digital healthcare company. The transaction was valued at approximately $38 million, with eMed set to acquire all outstanding shares of Science 37 for $5.75 per share in cash....more
Business Wire • May 9, 2023
Science 37 reported its financial results for the first quarter ended March 31, 2023, highlighting revenue growth and progress in expanding its decentralized clinical trial platform and services. This was one of their last earnings reports as a public company before the acquisition agreement....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Science 37, are just a search away.